AGC Biologics appoints new General Manager for Japan

Kagami-san has the expertise and experience to lead our Chiba site in the growth and achievement of our stated goals and objectives.

AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced the appointment of Naofumi Kagami as Site Head/General Manager of the Chiba, Japan facility. Kagami-san will provide leadership and site management to ensure the continued execution of world-class contract development and manufacturing services.

Kagami-san brings 25 years of industry experience to his role. Prior to joining AGC Biologics, he worked for Roche Diagnostics, Lonza and Sartorius Stedim in Japan in R&D, marketing and sales roles of increasing leadership responsibility for the life science and bio-manufacturing markets. He holds a Master of Science degree in Biochemistry and Biophysics from the University of Tokyo Graduate School.   

"We are pleased to have Kagami-san, a standout leader within the Life Sciences industry, join our world class team at AGC Biologics," said Kasper Moller, AGC Biologics Chief Technology Officer. "The role of Site Head/General Manager of the Chiba facility is essential to our operation's expansion and growth.

He will support the continuous growth of the Chiba facility while working closely with colleagues in Copenhagen, Heidelberg and Seattle to ensure the business leverages and integrates AGC Biologics combined global capabilities.

-----------------------------------------------------------------------
Editor's Note: For any copyright disputes involving the content,
please email: Julia.Zhang@ubmsinoexpo.com to delete.